和誉-B(02256.HK)贝捷迈®NDA获FDA受理，用于治疗腱鞘巨细胞瘤

Core Viewpoint - The new drug application (NDA) for the oral, highly selective, and effective small molecule CSF-1R inhibitor, Beijiemai® (ABSK021), developed by the subsidiary of He Yu-B (02256.HK), has been officially accepted by the U.S. Food and Drug Administration (FDA) for the systemic treatment of patients with tenosynovial giant cell tumor (TGCT) [1]. Group 1 - The drug Beijiemai® is a novel oral treatment targeting CSF-1R, indicating a significant advancement in the therapeutic options for TGCT patients [1]. - The acceptance of the NDA by the FDA marks a critical milestone for the company and its product development pipeline [1].